SEC Form 4 · accession 0001209191-17-052216
HARVARD BIOSCIENCE INC · HBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Uveges
Director
Period of report
Sep 7, 2017
Accepted (ET)
Sep 11, 2017 · 4:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001123494
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 7, 2017 | M | 23,720 | $2.28 | A | 188,440 | D | |
| Common StockF2,F3 | Sep 7, 2017 | F | 16,640 | $3.25 | D | 171,800 | D | |
| Common StockF4 | Sep 7, 2017 | M | 22,545 | $2.59 | A | 194,345 | D | |
| Common StockF2,F5 | Sep 7, 2017 | F | 17,967 | $3.25 | D | 176,378 | D | |
| Common StockF6 | Sep 7, 2017 | M | 21,213 | $2.56 | A | 197,591 | D | |
| Common StockF2,F7 | Sep 7, 2017 | F | 16,709 | $3.25 | D | 180,882 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F8 | $2.28 | Sep 7, 2017 | M | 23,720 | D | May 21, 2013 | May 21, 2019 | Common Stock, par value $0.01 per share | 23,720 | 0 | D |
| Stock option (right to buy)F8 | $2.59 | Sep 7, 2017 | M | 22,545 | D | Jun 4, 2014 | Jun 4, 2020 | Common Stock, par value $0.01 per share | 22,545 | 0 | D |
| Stock option (right to buy)F8 | $2.56 | Sep 7, 2017 | M | 21,213 | D | Jun 1, 2016 | Jun 1, 2022 | Common Stock, par value $0.01 per share | 21,213 | 0 | D |
Explanation of responses
- F1Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 11,150 restricted stock units which vest quarterly in equal installments on September 30, 2017 and December 31, 2017; and (c) 145,990 shares of common stock held by the Reporting Person.
- F2Represents the number of shares of common stock that the Reporting Person attested to the ownership thereof in accordance with the Issuer's Third Amended and Restated 2000 Stock Option and Incentive Plan, as amended, in connection with the payment of the option exercise price. With respect to each option exercise, the Issuer only delivered the net amount of the option shares (after reducing the option shares by the amount of shares subject to such attestation) to the Reporting Person and such attestation shares were not sold by the Reporting Person or delivered to the Issuer. Nevertheless, the SEC deems such exercise and related attestation to be a disposition of shares for purposes of Section 16(a) of the Securities Exchange Act of 1934.
- F3Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 11,150 restricted stock units which vest quarterly in equal installments on September 30, 2017 and December 31, 2017; and (c) 129,350 shares of common stock held by the Reporting Person.
- F4Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 11,150 restricted stock units which vest quarterly in equal installments on September 30, 2017 and December 31, 2017; and (c) 151,895 shares of common stock held by the Reporting Person.
- F5Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 11,150 restricted stock units which vest quarterly in equal installments on September 30, 2017 and December 31, 2017; and (c) 133,928 shares of common stock held by the Reporting Person.
- F6Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 11,150 restricted stock units which vest quarterly in equal installments on September 30, 2017 and December 31, 2017; and (c) 155,141 shares of common stock held by the Reporting Person.
- F7Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 11,150 restricted stock units which vest quarterly in equal installments on September 30, 2017 and December 31, 2017; and (c) 138,432 shares of common stock held by the Reporting Person.
- F8Represent the exercise of stock options granted pursuant to the Issuer's 2000 Stock Option and Incentive Plan, as amended.
Remarks
This form is signed under power of attorney.